A Multicenter Open-label Extension Study To Assess Long-term Safety Of PF-00547659 In Subjects With Crohn's Disease OPERA II
Phase of Trial: Phase II
Latest Information Update: 13 May 2018
At a glance
- Drugs SHP 647 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms OPERA II
- Sponsors Pfizer; Shire
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2016.
- 31 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2016.